Cardinal Manufactures 10% Gain In 1Q: Rx Stocks Stay Out Of Favor
Executive Summary
Cardinal's expanding manufacturing capacity is enhancing its image with investors who are attracted to the pharmaceutical sector but wary of the risks of drug development
You may also be interested in...
Iraq War Rally Helps Rx Stocks; Investors Adjust To Diminished Expectations?
Pfizer's steady progress toward closing the Pharmacia acquisition is giving the company a winning profile on Wall Street against the backdrop of a broader market rally fueled by the U.S. war in Iraq
Iraq War Rally Helps Rx Stocks; Investors Adjust To Diminished Expectations?
Pfizer's steady progress toward closing the Pharmacia acquisition is giving the company a winning profile on Wall Street against the backdrop of a broader market rally fueled by the U.S. war in Iraq
Cardinal To Run Xigris Emergency Distribution Via Acquisition Of Syncor
Cardinal will be the emergency supplier of Lilly's sepsis agent Xigris following the wholesaler's acquisition of the nuclear pharmacy company Syncor